The Society for Cardiovascular Angiography & Interventions (SCAI) has published an expert consensus statement that provides ...

WASHINGTON—The Society for Cardiovascular Angiography & Interventions (SCAI) has published an expert consensus statement that provides ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Zovighian said the transition to CEO has been relatively smooth since he joined Edwards in 2015 and spent eight years in ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

FARGO, N.D. – Sanford Health Fargo was named as one of the nation’s 50 Top Cardiovascular Hospitals according to an independent quality analysis based on a balanced scorecard provided by Premier, Inc.

Minimally invasive heart procedures like transcatheter aortic valve replacement (TAVR) and MitraClip placement to treat mitral regurgitation can improve quality of life, and even be lifesaving, for ...

37,249 people played the daily Crossword recently. Can you solve it faster than others?37,249 people played the daily Crossword recently. Can you solve it faster than others? EXCLUSIVE: John Goodman ...

As the company faces headwinds in its core Transcatheter Aortic Valve Replacement (TAVR) business, it simultaneously sees promising growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Stifel upgrades Edwards Lifesciences to Buy, citing TAVR growth potential and FDA label expansion in 2025. Edwards' Critical Care sale and focus on structural heart could drive higher valuation ...